← All trials
NCT02795416
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2016
- Primary completion
- Mar 1, 2017
- Completion date
- Mar 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- NovartisLead sponsor
- Karadeniz Technical UniversityOverall official - principal investigator
- University of AnkaraOverall official - principal investigator
- Izmir Bozyaka Training and Research HospitalOverall official - principal investigator
- Gaziantep UniversityOverall official - principal investigator
- Mersin UniversityOverall official - principal investigator
- Ege UniversityOverall official - principal investigator
- Istanbul UniversityOverall official - principal investigator
- Akdeniz UniversityOverall official - principal investigator
- Erciyes UniversityOverall official - principal investigator
- Uludag UniversityOverall official - principal investigator
- Hacettepe UniversityStudy director
- Istanbul UniversityStudy director
- Marmara UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.